-
1
-
2
-
3دورية أكاديمية
-
4
-
5
-
6دورية أكاديمية
الإتاحة: https://doi.org/10.1158/2767-9764.24574045.v1Test
https://figshare.com/articles/journal_contribution/Supplementary_Table_S3_from_Mathematical_Modeling_Identifies_Optimum_Palbociclib-fulvestrant_Dose_Administration_Schedules_for_the_Treatment_of_Patients_with_Estrogen_Receptor_positive_Breast_Cancer/24574045Test -
7دورية أكاديمية
الإتاحة: https://doi.org/10.1158/2767-9764.24574069.v1Test
https://figshare.com/articles/journal_contribution/Supplementary_Fig_S4_from_Mathematical_Modeling_Identifies_Optimum_Palbociclib-fulvestrant_Dose_Administration_Schedules_for_the_Treatment_of_Patients_with_Estrogen_Receptor_positive_Breast_Cancer/24574069Test -
8دورية أكاديمية
الإتاحة: https://doi.org/10.1158/2767-9764.24574105.v1Test
https://figshare.com/articles/journal_contribution/Supplementary_Appendix_S2_from_Mathematical_Modeling_Identifies_Optimum_Palbociclib-fulvestrant_Dose_Administration_Schedules_for_the_Treatment_of_Patients_with_Estrogen_Receptor_positive_Breast_Cancer/24574105Test -
9
-
10